All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-03-20T10:15:34.000Z

The impact on revised IMWG diagnostic criteria of new findings regarding BM aspiration and BM biopsy

Mar 20, 2017
Share:

Bookmark this article

In a letter to the editor of the Blood Cancer Journal, N. Lee and colleagues from the Seoul National University Hospital, Korea, described their findings regarding discrepancies between the percentage of plasma cells (PCs) as assessed by bone marrow (BM) aspiration (BMA) and BM biopsy (BMB). With new guidelines (issued by the International myeloma working group, IMWG) placing more emphasis on the PC percentage, and less emphasis on previously used CRAB symptoms (hypercalcemia, renal insufficiency, anemia, bone lesion), the need for accurate measurement of PC percentage is critical. Previous measurements of BMA did not take into account dilution of peripheral blood and there was no consensus regarding the volume taken, resulting in significant user error. In addition, routine methods to calculate PC percentage using BMB lacked objectivity.

Currently, the presence of clonal PC >10% is the main indicator for Multiple Myeloma (MM). The new guidelines indicate that BMB can be used in addition to BMA to assess PC percentage and that in cases of discrepancy, the higher value for either method should be considered. Therefore, this study set out to evaluate the percentage PC of BMB in patients with a low measured BMA PC (<10%), and to track the conversion rate from BMA PC (<10%) to BMB PC (≥10%), in order to assess user error and to compare PC estimates using the two different methods.

Key Highlights

  • Pts enrolled with newly diagnosed MM (NDMM) = 389
  • BMA PC<10% = 67 pts; 58 were available for analysis of BMB
  • CD138 staining was used for image analysis of BM sections
  • BMB PC count ≥ 10% = 55 pts and <10% = 3 pts
  • Mean PC% in BMB = 52.9%; SD = 30.7
  • Adequate BMA quality = 39.7%; mild to severe dilution = 60.3%
  • Most pts with diluted BMA had increased PC% upon BMB
  • Pts were divided into two groups on the basis of BMA PC ≥10% or <10%
  • Pts with BMA PC<10% were further subdivided into two groups on the basis of BMB PC% ≥10% or <10%
  • Median OS: high BMB PC% = 93.2 months vs. low BMB PC% = 67.9 months (p=0.010)
  • Median OS: BMA PC% = no significant difference
  • Conversion rate of BMA PC <10% to >10% in BMB = 75% (55/73 pts)
  • Majority of pts with <10% PC in BMA had diluted BM aspiration and less diffuse PC in BMB
  • BMB PC% moderately correlated with corresponding end organ disorders, quantitative FISH results, and OS in patients with low BMA PC%

Obtaining an accurate PC count has become increasingly important for the accurate diagnosis of MM. The authors established that the BMB PC count provides more diagnostic relevance than BMA, and better reflects the recently revised criteria, although combined evaluation (of both BMA and BMB) is more reliable for diagnosis. The use of CD138 staining and image analysis for PC% by BMB enables greater objectivity and decreased user error, and is practical enough for routine clinical use.

  1. Lee N. et al. Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma. Blood Cancer J. 2017 Feb 17;7(2):e530. DOI:10.1038/bcj.2017.14.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox